Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Semaglutide and NNC0480-0389 with Oral Contraceptives
NCT05153564Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NNC0480-0389 in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoints: Area under the ethinylestradiol plasma concentration time curve during a dosing interval (0 to 24 hours) at steady state and Area under the levonorgestrel plasma concentration time curve during a dosing interval (0 to 24 hours) at steady state. Started Dec 2021; status: completed.
02
Drugs
NNC0480-0389
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05153564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153564.